Furthermore, mutations in PIK3CA and loss of PTEN indicate hyperactivation of the PI3K/AKT/mTOR pathway, suggesting that targeted inhibitors, such as alpelisib (a PI3Kα‐specific inhibitor) [36], ipatasertib (an AKT inhibitor) [37], and everolimus (an mTOR inhibitor) [38, 39] could effectively suppress tumor growth, especially when combined with other therapies. Here, PTEN is linked to neoplasm.